BOEHRINGER SEEKS TO ENJOIN LIFESCAN FROM MAKING GLUCOSE MONITORS BASED ON ACCUTREND DM TECHNOLOGY; SUIT CHARGES J&J UNIT WITH INDUSTRIAL ESPIONAGE
This article was originally published in The Gray Sheet
Boehringer Mannheim Corporation is seeking to enjoin Johnson & Johnson's LifeScan subsidiary from selling blood glucose monitors that incorporate technology from its Accutrend DM monitor. In a suit filed June 19 in the U.S. District Court in Indianapolis, Boehringer alleges that LifeScan illegally obtained information on the monitor through industrial espionage and should be barred "from marketing any products based on the information for a period of time equal to that it would have taken LifeScan and [J&J] to develop those products independently."
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.